Jason Fangusaro

Flow diagram summarizing duration of therapy and DLTs for patients on both strata.

Mean (±SD) serum sotigalimab concentration–time profiles at the 0.6 mg/kg dose (DL3) in Cycle 1 and Cycle 2 (pooled across strata). Sampling occurred pre-dose, at end of infusion (EOI), and at 4, 24 ± 1, and 168 ± 4 hours from infusion start; nominal times are plotted. Concentrations at pre-dose and 168 hours were BLQ (0.010 µg/mL). Error bars represent SD; n per timepoint: Cycle 1, 15–17; Cycle 2, 12–13.

Swimmers plot showing time on treatment for each patient (sorted by stratum and longest duration on treatment).

Select cytokine profiles of those cytokines IL-8, IFN-γ, IL-6, and TNF-α which met limit of detection across the cohort.

Patient characteristics for eligible subjects (n=31)

Metadata summary of all deidentified patients used for all analyses.

Supplementary Table 3 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG

Representativeness of Study Participants

Supplementary Table 4 from Pediatric Brain Tumor Consortium Phase I Study of CD40 Agonist Sotigalimab in Pediatric and Young Adult Patients with Recurrent CNS Tumors and Newly Diagnosed DIPG

Purpose: The PBTC-051 study is the first pediatric evaluation of a CD40 agonist and assessed the safety, pharmacokinetics, and preliminary efficacy of sotigalimab in children and young adults with recurrent or progressive malignant central nervous system (CNS) tumors (stratum 1) and post-radiation pre-progression diffuse intrinsic pontine glioma (DIPG) (stratum 2). Patients and methods: This prospective phase 1 study conducted by the Pediatric Brain Tumor Consortium evaluated sotigalimab using a 3+3 design for dose escalation. Immune pharmacodynamics were assessed with RNA transcript analysis, T cell receptor sequencing, and cytokine profiling. Results: 31 eligible patients were enrolled (stratum 1: 20, stratum 2: 11). The stratum 1 recommended phase 2 dose was 0.6 mg/kg every 3 weeks; the stratum 2 maximum tolerated dose was 0.3 mg/kg every 3 weeks. Five patients had dose-limiting toxicities. No patients had an objective response. For stratum 1, 6-month and 12-month progression-free survivals (PFS) were 13.3% (standard error [SE], 8.1%) and 6.7% (SE, 6.2%), respectively; for stratum 2, 6-month PFS and overall survival were 31.2% (SE, 14.8%) and 44.4% (SE, 16.6%), respectively. At all dose levels, the maximum serum concentration was reached at the end of infusion; no drug accumulation was detected. More than 40% of patients developed anti-drug antibodies. Signaling pathways associated with activated antigen presenting cells and T cells were enriched in patients with higher PFS, while increased loss of heterozygosity was noted in patients with lower PFS. Conclusions: Sotigalimab was well-tolerated in pediatric patients with recurrent or progressive CNS tumors and post-radiation pre-progression DIPG.